September 13, 2022 (Chicago, IL) — Synapticure has launched a novel two-month remote monitoring test program, which will integrate the use of at-home respiratory monitoring equipment into the care that you receive from Synapticure. The test program has two main goals: first, to ensure that the partner, device, and software selected meet patients’ needs; and second, to ensure that we are able to provide patients and clinicians with information about their Slow Vital Capacity (SVC).
Why is monitoring respiratory function important?
Monitoring respiratory function is an extremely important component of comprehensive ALS care and is performed at regular intervals to monitor how disease progression affects breathing. Prior research has demonstrated that monitoring respiratory function at home in ALS patients can decrease the number and cost of hospitalizations and emergency room visits. As one study reported, remote monitoring of respiratory function at home was not only “feasible and safe … [but also] increased survival, while decreasing health care costs as determined by the number of in-office and emergency room visits and hospital admissions.”
With this test program, we provide the enrolled patients with a device that can be used to obtain SVC, which is in turn regularly monitored by their Synapticure care team. This data can be used by the care team to take proactive steps to intervene when there is a clinically relevant drop in SVC. the goal is to identify when a patient may benefit most from starting non-invasive ventilation, like BiPAP. A BiPAP is a conservative measure that can potentially delay the need for invasive tracheostomy or mechanical ventilation.
What happens after the test program?
At the successful conclusion of the test program, Synapticure will launch remote respiratory monitoring for all of its patients.
We would like to thank the test program patients who have enrolled. At this time, the test program is full. We are excited to serve our broader Synapticure patient population soon.
How do I find out more about Synapticure’s remote respiratory monitoring?
If you are a current Synapticure patient and are interested in learning about remote respiratory monitoring, please contact your care coordinator. If you are new to Synapticure, please enroll here, as the remote respiratory program will only be available for patients seen by Synapticure Physicians (Typically as part of your broader care team). We look forward to serving you.
1 Lopes de Almeida JP, Pinto AC, Pereira J, Pinto S, de Carvalho M. Implementation of a wireless device for real-time Telemedical assistance of home-ventilated amyotrophic lateral sclerosis patients: a feasibility study. Telemed. J. E Health 2010;16(8):883–8. [PubMed]
2 Pinto A., Almeida J.P., Pinto S., Pereira J., Oliveira A.G., de Carvalho M. Home telemonitoring of non-invasive ventilation decreases healthcare utilisation in a prospective controlled trial of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2010;81(11):1238–1242. [PubMed]
3 Lopes de Almeida J.P., Pinto A., Pinto S., Ohana B., de Carvalho M. Economic cost of home-telemonitoring care for BiPAP-assisted ALS individuals. Amyotroph. Lateral Scler. 2012;13(6):533–537. [PubMed]
Synapticure is dedicated to creating the future of neurodegenerative disease patient care. Today, Synapticure is focused on providing better treatment and care for all people living with ALS through a full-stack teleneurology platform, built by and for those living with ALS. Co-founded by Brian Wallach, Sandra Abrevaya, Peter Wallach, Jason Langheier and Jonathan Hirsch, Synapticure is headquartered in Chicago, Illinois. To learn more, please visit synapticure.com or follow us on Twitter, LinkedIn, Facebook, and Instagram for updates.
ALS is 100% fatal and affects more than 30,000 people in the U.S. The lifetime risk of developing ALS is 1 in 300, the same as Multiple Sclerosis. Each year, more than five thousand people are diagnosed with ALS in the US alone. This number is expected to nearly double by 2060. People living with ALS, on average, live two to five years after diagnosis, and nearly half live more than 50 miles away from the closest ALS multidisciplinary clinic.
About Parkinson’s Disease
Parkinson's disease is a progressive neurodegenerative disease that causes nerve cells (or neurons) in the area of the brain that controls movement to weaken and/or die. More than 10 million people worldwide are currently living with Parkinson's disease. The number of people diagnosed with with Parkinson’s Disease is expected to rise from 900,000 to 1.2 million by 2030. What causes Parkinson's remains largely unknown. Genetics cause about 10 to 15 percent of all Parkinson's. The other 85 to 90 percent of cases are classified as sporadic (or occasional). Although there is no cure, treatment options vary and include medications and surgery.